key: cord-0803329-8alxnc4x
authors: Ohashi, Hirofumi; Watashi, Koichi; Saso, Wakana; Shionoya, Kaho; Iwanami, Shoya; Hirokawa, Takatsugu; Shirai, Tsuyoshi; Kanaya, Shigehiko; Ito, Yusuke; Kim, Kwang Su; Nomura, Takao; Suzuki, Tateki; Nishioka, Kazane; Ando, Shuji; Ejima, Keisuke; Koizumi, Yoshiki; Tanaka, Tomohiro; Aoki, Shin; Kuramochi, Kouji; Suzuki, Tadaki; Hashiguchi, Takao; Maenaka, Katsumi; Matano, Tetsuro; Muramatsu, Masamichi; Saijo, Masayuki; Aihara, Kazuyuki; Iwami, Shingo; Takeda, Makoto; McKeating, Jane A.; Wakita, Takaji
title: Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment
date: 2021-03-26
journal: iScience
DOI: 10.1016/j.isci.2021.102367
sha: 8a44fe7eec02fb3c92a0d69a5cd3123862af69df
doc_id: 803329
cord_uid: 8alxnc4x

Antiviral treatments targeting the coronavirus disease 2019 are urgently required. We screened a panel of already-approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the drug candidates such as Remdesivir and Chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory drug Cepharanthine and HIV protease inhibitor Nelfinavir. Cepharanthine inhibited SARS-CoV-2 entry through the blocking of viral binding to target cells, whilst Nelfinavir suppressed viral replication partly by protease inhibition. Consistent with their different modes of action, synergistic effect of this combined treatment to limit SARS-CoV-2 proliferation was highlighted. Mathematical modeling in vitro antiviral activity coupled with the calculated total drug concentrations in the lung predicts that Nelfinavir will shorten the period until viral clearance by 4.9-days and the combining Cepharanthine/Nelfinavir enhanced their predicted efficacy. These results warrant further evaluation of the potential anti-SARS-CoV-2 activity of Cepharanthine and Nelfinavir.

Antiviral treatments targeting the coronavirus disease 2019 are urgently required. We screened a 52 panel of already-approved drugs in a cell culture model of severe acute respiratory syndrome 53

coronavirus-2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the 54 drug candidates such as Remdesivir and Chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory 55

drug Cepharanthine and HIV protease inhibitor Nelfinavir. Cepharanthine inhibited SARS-CoV-2 entry 56 through the blocking of viral binding to target cells, whilst Nelfinavir suppressed viral replication partly by 57 protease inhibition. Consistent with their different modes of action, synergistic effect of this combined 58 treatment to limit SARS-CoV-2 proliferation was highlighted. Mathematical modeling in vitro antiviral 59 activity coupled with the calculated total drug concentrations in the lung predicts that Nelfinavir will 60

shorten the period until viral clearance by 4.9-days and the combining Cepharanthine/Nelfinavir 61 enhanced their predicted efficacy. These results warrant further evaluation of the potential 62

anti-SARS-CoV-2 activity of Cepharanthine and Nelfinavir. of these drugs are pending, however, it would be prudent to have a pipeline of additional drug 80

candidates available for clinical trials. 81

In this study, we screened a panel of already-approved drugs in a SARS-CoV-2 infection cell culture 82 assay and identified two, Cepharanthine (CEP) and Nelfinavir (NFV), that showed more potent antiviral 83 activity compared to RDV and other drugs currently being trialed. Our in vitro, in silico, and cell culture 84

analyses demonstrate that CEP and NFV inhibit SARS-CoV-2 entry and RNA replication, respectively. 85

Their different modes of action provided synergistic antiviral effects. We also mathematically predicted 86 the potential antiviral efficacy of the single treatment of either CEP and NFV, and its combination in 87 clinical settings. These data cumulatively provide evidences for anti-SARS-CoV-2 potentials of CEP 88 and NFV. 89 90 91

We established a cell-based drug screening system to identify compounds that protect cells from 94 SARS-CoV-2-induced cytopathology (Fig. 1A expression 24 h post-inoculation by immunofluorescence (Fig. 1C , red) and immunoblotting (Fig. 1D ). 108

Both CEP and NFV significantly reduced N protein expression along with the positive control drug 109

candidates LPV, CLQ, and RDV. We confirmed that CEP and NFV inhibit SARS-CoV-2 proliferation in 110 a human-derived lung epithelial cell line Calu-3 cells (Fig. 1E) . concentrations up to 64 µM (Fig. 2B ). The concentration of drugs required to inhibit 50% (IC 50 ) or 90% 120

(IC 90 ) of virus proliferation along with their 50% cytotoxicity (CC 50 ) were estimated by Median effect 121 model and are listed in Fig. 2A and B . These experiments highlight a > 70-fold window (CC 50 /IC 50 ) 122

where CEP and NFV can inhibit SARS-CoV-2 proliferation with minimal toxicity. In summary, our 123 screen identified two compounds that inhibit SARS-CoV-2 infection with high potency. group of Ser494 and the aromatic rings are close to contact with the aromatic residues (Tyr449, Tyr453, 147

Tyr489 and Phe490) at the binding interface with ACE2. Binding free energy of CEP molecule was 148 estimated as -24.26 kcal/mol using MM-GBSA calculation (Schrödinger, LLC). To assess this model we 149

investigated whether CEP inhibits SARS-CoV-2 particle binding to the cell surface or subsequent 150 internalization into cells. We measured viral binding to cells by pre-chilling cells to prevent particle SARS-CoV-2 particle attachment to the cells (Fig. 4B ). These data demonstrate that CEP inhibits 157 SARS-CoV-2 particle binding to cells. 158

Nelfinavir potently targets SARS-CoV-2 main protease 160 We conducted in silico docking simulation screenings to identify compounds from an approved library 161 that interact with the SARS-CoV-2 encoded main protease (Methods). Interestingly, NFV was identified 162

amongst the top 1.5% ranking compounds (Fig. 5A , cyan stick: NFV, green: main protease). Our 163 docking model predicts that NFV interacts with the SARS-CoV-2 protease active site pocket and would 164 block substrate recruitment (Fig. 5A) . To assess this model we evaluated the activity of recombinant 165 SARS-CoV-2 main protease in vitro protease assay (Methods). We showed that NFV inhibited the 166 catalytic activity of the SARS-CoV-2 encoded main protease in a dose-dependent manner, and its IC 50 167 was calculated to be 37 µM (Fig. 5B) . These in vitro and in silico data suggest that NFV potentially 168 targets the main protease, but its inhibition activity is likely to be weaker than that to block SARS-CoV-2 169

replication. 170 171

Both CEP and NFV show anti-SARS-CoV-2 activity at the concentration ranges observed in patients, 173

where the serum C max of both drugs are 2.3 and 6.9 µM (by administration of 500 mg NFV orally and of 174 100 mg CEP by intravenous injection), respectively (Markowitz et al., 1998; Yasuda et al., 1989) . Since 175 CEP and NFV have different mode of actions, we examined their potential for synergistic effects. 176

Antiviral activity and cell viability were determined by qPCR enumeration of viral RNA and MTT activity, 177

respectively, following treatment with each compound alone or in combination ( Fig. 6A and B) . For 178 these experiments, we infected cells with lower amounts of SARS-CoV-2 (MOI=0.001) and treated 179

compounds at more frequent points of concentrations than used in our earlier assay, for securing an 180 accurate estimation. Single treatment with CEP or NFV reduced viral RNA in a dose-dependent 181 manner and co-treatment further reduced viral RNA levels ( Fig. 6A ): e.g. CEP (3.20 µM) or NFV (2.24 182 µM) alone reduced viral RNA to 6.3% or 5.8% of untreated control, respectively, however, when 183 J o u r n a l P r e -p r o o f combined they reduced viral RNA level to 0.068%. Higher doses of the CEP/NFV combination (4 µM 184 each) reduced the viral RNA to undetectable levels. We compared the observed experimental antiviral 185 activity (Fig. 6A, Supporting Fig. S2A ) with theoretical predictions calculated using a classical Bliss 186

independence method that assumes drugs act independently (Supporting Note, Supporting Fig. S2B ) 187 (Greco et al., 1995; Koizumi and Iwami, 2014) . The difference between the observed values and 188 theoretical predictions suggest that CEP and NFV exhibit a synergistic activity over a broad range of 189 concentrations (Fig. 6C red: synergistic effect) . drug, we can model the impact on viral burden following drug administration (Fig. 7B , Supporting Note, 201

Supporting Fig. S3 ). From the viral dynamics data in Fig. 7B , we calculated the cumulative viral RNA 202 burden (i.e., area under the curve of viral load) (Fig. 7C , upper) and the time required to reduce the viral 203 load to undetectable levels (Fig. 7C, lower) . Our modeling predicts that NFV monotherapy would 204 reduce the cumulative viral load by 92.1% (Fig. 7C , upper, red) and would require 10.3 days to eliminate 205 virus (Fig. 7B , upper left, red), 4.9 days shorter than untreated controls (Fig. 7C, lower, red) . In contrast, 206

orally administered CEP shows a minimal effect on the viral load (Fig. 7B , lower left, green), most likely 207 reflecting low drug concentrations, while intravenous delivery of CEP reduces the cumulative viral load 208 ( Fig. 7B -C, green) and shortens the period for virus elimination (Fig. 7C , lower, green) because of 209 achieving enough drug concentration (see Discussion). Importantly, co-administering NFV (oral) and 210 CEP (intravenous drip) resulted in a more rapid decline in viral RNA, with undetectable levels 6.15 days 211 earlier than untreated controls and 1.23 days earlier than NFV alone (Fig. 7C, orange) . Another 212 advantage of combination treatment is discussed in Discussion. In summary, our prediction shows the 213 potential antiviral efficacy of NFV and CEP, and its combined treatment that facilitates SARS-CoV-2 214 elimination. along with viral binding and docking simulation analysis suggest that CEP predominantly inhibits 223

virus-cell binding. We also have a preliminary data by surface plasmon resonance analysis showing a 224 potential interaction between CEP and the S protein, speculating its mode of action and which needs to 225 be further analyzed in the future. These data are consistent with a previous paper reporting that CEP Our mathematical modeling studies assess how drug candidates can suppress and eliminate 246 SARS-CoV-2. Based on the reported lung distribution/concentration of CEP and NFV in patients, we 247

predicted that NFV at clinical doses can maintain significant antiviral effects throughout the treatment 248 period and reduce SARS-CoV-2 RNA burden that results in shortening the time required to eliminate 249

infection. In contrast, we predict that oral administration of CEP will have limited antiviral effect due to 250 its low concentration in vivo. However, intravenous delivery of CEP achieves higher drug 251 concentrations especially accumulated in the lung (Yokoshima et al., 1986) , that enables sustained 252 antiviral activity. It is noteworthy that combining CEP with NFV further reduced the cumulative viral load should not preclude the clinical assessment of new antiviral agents. We here propose CEP and NFV 265 as potential antiviral drug candidates against COVID-19, and thus NFV is under clinical evaluation in a 266 multicenter randomized controlled trial in Japan (jRCT2071200023). 267

Limitations of the Study 269

In this study, we mainly used VeroE6/TMPRSS2 cells and applied the dose-dependent antiviral 270 activity in these cells ( Fig. 2A) to predict the drug efficacy in patients (Fig. 7) . More physiologically 271 relevant cell models such as primary human respiratory/lung cells in air-liquid interface culture and 272

organoids, or presumably in vivo infection models would be needed to strengthen the data. As well, our 273 mathematical prediction was based on the total drug concentration in the lung, although free drug that 274

does not non-specifically bind to proteins is believed to be pharmacologically active. There is no 275

information available on the free CEP and NFV concentration in the lung tissue. 276

Resource Availability 278

Lead Contact 279

Further information and requests for resources and reagents should be directed to and will be fulfilled by 280

the Lead Contact, Koichi Watashi: kwatashi@nih.go.jp 281 282

Materials Availability 283

This study did not generate new unique materials. 284

Data and Code Availability 286

All data are included in the article and Supplemental Information and any additional information will be 287 available from the lead contact upon request. 

Chloroquine could be used for the treatment of filoviral infections and other viral 319 infections that emerge or emerged from viruses requiring an acidic pH for infectivity

Cepharanthine: An update of its mode of action, pharmacological properties and 322 medical applications

The 325 pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Remdesivir for the Treatment of Covid-19 -Preliminary 329

A Randomized Trial of Hydroxychloroquine as 332

Postexposure Prophylaxis for Covid-19

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit 339 SARS-CoV-2 replication in vitro

Virus Attachment. Pharmacochemistry Library

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel 346 coronavirus (2019-nCoV) related coronavirus model

Intracellular and plasma pharmacokinetics of nelfinavir and M8 in 350 HIV-infected patients: relationship with P-glycoprotein expression

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

The search for synergy: a critical review from a 356 response surface perspective

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

In Silico Exploration of the Molecular Mechanism of Clinically 361 Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease

Potential Antiviral Options against SARS-CoV-2 Infection

Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Cepharanthine mitigates pro-inflammatory 370 cytokine response in lung injury induced by hemorrhagic shock/resuscitation in rats

Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine

Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Mathematical modeling of multi-drugs therapy: a challenge for 380 determining the optimal combinations of antiviral drugs

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Inhibition of SARS 386 pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection 390 in vitro

Viral dynamics in mild and severe cases of COVID-19

Screening of 395 drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease

A preliminary evaluation of nelfinavir mesylate, an inhibitor of 399 human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Identification of potential 406 molecules against COVID-19 main protease through structure-guided virtual screening approach

Binding site analysis of potential protease inhibitors of COVID-19 409 using AutoDock. Virusdisease. 1-6

Respiratory disease in rhesus 412 macaques inoculated with SARS-CoV-2

The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the 416

SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 417 infections

In vitro evaluation of antiviral activity of single and combined 420 repurposable drugs against SARS-CoV-2

Statins and the COVID-19 main protease: in silico evidence 424 on direct interaction

Comparative pathogenesis of COVID-19

MERS, and SARS in a nonhuman primate model

Preclinical pharmacokinetics and 431 distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease

The COVID-19 vaccine development landscape

Of chloroquine and COVID-19

Measurement of antiretroviral drugs in the lungs of 441 HIV-infected patients

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in 447 vitro

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Small molecules targeting severe acute respiratory syndrome human coronavirus

HIV protease inhibitor nelfinavir inhibits replication of 459 SARS-associated coronavirus

Pharmacokinetic disposition of cepharanthin 462 following single and multiple intravenous doses in healthy subjects

Studies on 465 metabolic fate of cepharanthine: Absorption, distribution, metabolism and excretion in rats

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China